First International Consensus Statement on the Clinical and Therapeutic Management of LHON published in the Journal of Neuro-Ophthalmology
(WorldNews Switzerland)

Santhera Pharmaceuticals Holding AG Hammerstrasse 49 4410 Liestal / Switzerland Phone +41 61 906 89 50 Fax +41 61 906 89 51 www.santhera.com First International Consensus Statement on the Clinical and Therapeutic Management of LHON published in the Journal of Neuro-Ophthalmology Liestal, Switzerland, October 23, 2017 - Santhera Pharmaceuticals (SIX:SANN) announces that the first International Consensus Statement on the Clinical and Therapeutic Management of Leber`s Hereditary Optic Neuropathy (LHON) has been published in the Journal of Neuro- Ophthalmology. The Consensus Statement reflects the independent views from a panel of world-leading experts in the management of patients with LHON. It...